JP2022549680A5 - - Google Patents

Info

Publication number
JP2022549680A5
JP2022549680A5 JP2022519131A JP2022519131A JP2022549680A5 JP 2022549680 A5 JP2022549680 A5 JP 2022549680A5 JP 2022519131 A JP2022519131 A JP 2022519131A JP 2022519131 A JP2022519131 A JP 2022519131A JP 2022549680 A5 JP2022549680 A5 JP 2022549680A5
Authority
JP
Japan
Prior art keywords
dendrimer
group
composition
building unit
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022519131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549680A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2020/051028 external-priority patent/WO2021056077A1/en
Publication of JP2022549680A publication Critical patent/JP2022549680A/ja
Publication of JP2022549680A5 publication Critical patent/JP2022549680A5/ja
Pending legal-status Critical Current

Links

JP2022519131A 2019-09-26 2020-09-25 治療用デンドリマー Pending JP2022549680A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2019903628 2019-09-26
AU2019903628A AU2019903628A0 (en) 2019-09-26 Therapeutic Dendrimer
AU2019904094A AU2019904094A0 (en) 2019-10-30 Therapeutic dendrimer
AU2019904094 2019-10-30
PCT/AU2020/051028 WO2021056077A1 (en) 2019-09-26 2020-09-25 Therapeutic dendrimer

Publications (2)

Publication Number Publication Date
JP2022549680A JP2022549680A (ja) 2022-11-28
JP2022549680A5 true JP2022549680A5 (https=) 2023-10-02

Family

ID=75164741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022519131A Pending JP2022549680A (ja) 2019-09-26 2020-09-25 治療用デンドリマー

Country Status (7)

Country Link
EP (1) EP4034169B1 (https=)
JP (1) JP2022549680A (https=)
KR (1) KR20220072851A (https=)
CN (1) CN114585389A (https=)
AU (1) AU2020354787A1 (https=)
CA (1) CA3152111A1 (https=)
WO (1) WO2021056077A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102948775B1 (ko) 2018-11-20 2026-04-03 스타파마 피티와이 리미티드 치료 덴드리머

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
AR042042A1 (es) * 2002-11-15 2005-06-08 Sugen Inc Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
JP5989294B2 (ja) * 2006-01-20 2016-09-07 スターファーマ・プロプライエタリー・リミテッドStarpharma Pty Ltd 修飾高分子
WO2011012722A1 (en) * 2009-07-31 2011-02-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
IN2014DN00101A (https=) * 2011-06-06 2015-05-15 Starpharma Pty Ltd
US20180326081A1 (en) * 2011-06-06 2018-11-15 Starpharma Pty Ltd Macromolecules
GB2551979A (en) * 2016-06-30 2018-01-10 Rs Arastirma Egitim Danismanlik Llac Sanayi Ticaret Ltd Cleavable polymer drug conjugates
TWI773730B (zh) * 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
KR102948775B1 (ko) * 2018-11-20 2026-04-03 스타파마 피티와이 리미티드 치료 덴드리머
JP7541978B2 (ja) * 2018-11-29 2024-08-29 スターファーマ ピーティーワイ エルティーディー 治療および画像化のためのデンドリマー

Similar Documents

Publication Publication Date Title
Venditto et al. Cancer therapies utilizing the camptothecins: a review of the in vivo literature
Sun et al. Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy
US20170266293A1 (en) Methods of treating cancers with therapeutic nanoparticles
CA2995029C (en) Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
JP2010540535A5 (https=)
JP2012532185A5 (https=)
RU2012151134A (ru) Логометрическая комбинаторная доставка лекарственных средств
JP2020503289A5 (https=)
Nguyen et al. Curcumin and paclitaxel co-loaded heparin and poloxamer p403 hybrid nanocarrier for improved synergistic efficacy in breast cancer
KR20140024833A (ko) 신규한 시티딘계 대사길항제의 고분자 유도체
TW200803842A (en) Antineoplastic combinations of temsirolimus and sunitinib malate
CN102164617A (zh) 在受试者体内实现持续的治疗药物浓度的组合物和方法
Xiao et al. Use of anticancer platinum compounds in combination therapies and challenges in drug delivery
US20120015900A1 (en) Cobalamin Taxane Bioconjugates
JP2022549680A5 (https=)
EP2737896B1 (en) Umirolimus micelle for the treating cancer
JP2018536655A5 (https=)
WO2014084378A1 (ja) 環状rgd配列含有ペプチドを含む抗癌剤
CN116133693A (zh) 载药的大分子及其制备方法
WO2018049017A1 (en) Block copolymer systems for local administration of toll-like receptor agonists
CN115844822A (zh) 一种口服载药胶束组合物及其制备方法
JP6580030B2 (ja) カンプトテシン誘導体とhsp90阻害剤の結合した高分子化合物及びその用途
JP6461088B2 (ja) 高分子化カンプトテシン誘導体及び高分子化hsp90阻害剤誘導体を含む医薬組成物
Hu et al. Current status of CPT and its analogues in the treatment of malignancies
CN104689336A (zh) 医药组合物或组合剂